Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Highlow study of low versus intermediate dose LMWH for prevention of recurrent VTE in pregnancy
NL-OMON55412Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of low molecular weight heparin calcium in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Recurrence of venous thromboembolism. Started Apr 2013; status: active, not recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON55412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55412.